Optimal blood pressure target in the elderly: rationale and design of the HOW to Optimize eLDerly systolic Blood Pressure (HOWOLD-BP) trial
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: The optimal systolic blood pressure (SBP) goal for elderly patients with hypertension, especially to reduce cardiovascular disease (CVD) incidence and improve outcome, is unclear. This study aimed to evaluate the beneficial effects of intensive treatment for hypertension on the incidence of CVD in elderly Korean patients. Methods: The HOW to Optimize eLDerly systolic Blood Pressure (HOWOLD-BP) trial is a multicenter, parallel-design, open-label, randomized controlled trial designed to evaluate whether intensive treatment (SBP ≤ 130 mmHg) will provide more benefits in lowering the incidence and mortality associated with CVD than standard treatment (SBP ≤ 140 mmHg) in elderly patients with hypertension aged ≥ 65 years. For this study, eleven university hospitals in Korea will enroll approximately 3,176 elderly patients with hypertension between 2019 and 2022. Patients will be requested to visit the clinic every 4 months for the first year and every 6 months thereafter for 36 months. Parameters, including clinic and home blood pressure, anthropometric and laboratory findings, and frailty assessments, will be collected according to the standardized protocol. The primary outcome is a composite of CVD (acute coronary syndrome, stroke, and heart failure) incidence and cardiovascular deaths. Results: As of December 2021, 1,655 participants had been enrolled in the study, including 831 patients in the standard group and 824 patients in the intensive group. Conclusions: The HOWOLD-BP trial is the first study performed in Korea to evaluate the beneficial effects of intensive blood pressure treatment on CVD in elderly patients with hypertension. The results of this study will help clarify the appropriate target SBP for this population.
Abstract
Background/Aims: The optimal systolic blood pressure (SBP) goal for elderly patients with hypertension, especially to reduce cardiovascular disease (CVD) incidence and improve outcome, is unclear. This study aimed to evaluate the beneficial effects of intensive treatment for hypertension on the incidence of CVD in elderly Korean patients. Methods: The HOW to Optimize eLDerly systolic Blood Pressure (HOWOLD-BP) trial is a multicenter, parallel-design, open-label, randomized controlled trial designed to evaluate whether intensive treatment (SBP ≤ 130 mmHg) will provide more benefits in lowering the incidence and mortality associated with CVD than standard treatment (SBP ≤ 140 mmHg) in elderly patients with hypertension aged ≥ 65 years. For this study, eleven university hospitals in Korea will enroll approximately 3,176 elderly patients with hypertension between 2019 and 2022. Patients will be requested to visit the clinic every 4 months for the first year and every 6 months thereafter for 36 months. Parameters, including clinic and home blood pressure, anthropometric and laboratory findings, and frailty assessments, will be collected according to the standardized protocol. The primary outcome is a composite of CVD (acute coronary syndrome, stroke, and heart failure) incidence and cardiovascular deaths. Results: As of December 2021, 1,655 participants had been enrolled in the study, including 831 patients in the standard group and 824 patients in the intensive group. Conclusions: The HOWOLD-BP trial is the first study performed in Korea to evaluate the beneficial effects of intensive blood pressure treatment on CVD in elderly patients with hypertension. The results of this study will help clarify the appropriate target SBP for this population.
참고문헌 (32)
- Ezzati M, "Selected major risk factors and global and regional burden of disease", Lancet, 360, pp.1347~1360 (2002)
- Kannel WB, "Historic perspectives on the relative contributions of diastolic and systolic blood pressure elevation to cardiovascular risk profile", Am Heart J, 138(3 Pt 2), pp.205~210 (1999)
- Ostchega Y, "Hypertension prevalence among adults aged 18 and over : United States, 2017-2018", NCHS Data Brief, 364, pp.1~8 (2020)
- 김현창, "Korea hypertension fact sheet 2020: analysis of nationwide population-based data", Clinical Hypertension, 27(2), pp.66~69 (2021), 대한고혈압학회[DOI]
- Staessen JA, "Cardiovascular protection and blood pressure reduction : a meta-analysis", Lancet, 358, pp.1305~1315 (2001)
- Beckett NS, "Treatment of hypertension in patients 80 years of age or older", N Engl J Med, 358, pp.1887~1898 (2008)
- JATOS Study Group, "Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients(JATOS)", Hypertens Res, 31, pp.2115~2127 (2008)
- Ogihara T, "Target blood pressure for treatment of isolated systolic hypertension in the elderly : valsartan in elderly isolated systolic hypertension study", Hypertension, 56, pp.196~202 (2010)
- SPRINT Research Group, "A randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373, pp.2103~2116 (2015)
- Williamson JD, "Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years : a randomized clinical trial", JAMA, 315, pp.2673~2682 (2016)
- Zhang W, "Trial of intensive blood-pressure control in older patients with hypertension", N Engl J Med, 385, pp.1268~1279 (2021)
- Bavishi C, "Outcomes of intensive blood pressure lowering in older hypertensive patients", J Am Coll Cardiol, 69, pp.486~493 (2017)
- Liu L, "The Felodipine Event Reduction(FEVER)Study : a randomized long-term placebo-controlled trial in Chinese hypertensive patients", J Hypertens, 23, pp.2157~2172 (2005)
- Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
- Williams B, "2018 ESC", ESH guidelines for the management of arterial hypertension, 2018, pp.39, 3021~3104
- Hae-Young Lee, "2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension", Clinical Hypertension, 25(4), pp.51~74 (2019), 대한고혈압학회[DOI]
- 이주희, "Current status and therapeutic considerations of hypertension in the elderly", The Korean Journal of Internal Medicine, 34(4), pp.687~695 (2019), 대한내과학회[DOI]
- Freeman R, "Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome", Clin Auton Res, 21, pp.69~72 (2011)
- Lawton MP, "Assessment of older people : self-maintaining and instrumental activities of daily living", Gerontologist, 9, pp.179~186 (1969)
- Charlson ME, "A new method of classifying prognostic comorbidity in longitudinal studies : development and validation", J Chronic Dis, 40, pp.373~383 (1987)
- 정희원, "The Korean version of the FRAIL scale: clinical feasibility and validity of assessing the frailty status of Korean elderly", The Korean Journal of Internal Medicine, 31(3), pp.594~600 (2016), 대한내과학회
- Lee JY, "Brief screening for mild cognitive impairment in elderly outpatient clinic : validation of the Korean version of the Montreal Cognitive Assessment", J Geriatr Psychiatry Neurol, 21, pp.104~110 (2008)
- Kim MH, "Cross-cultural adaptation and validation of the Korean version of the EQ-5D in patients with rheumatic diseases", Qual Life Res, 14, pp.1401~1406 (2005)
- Ogihara T, "valsartan in elderly isolated systolic hypertension(VALISH)study : rationale and design", Hypertens Res, 27, pp.657~661 (2004)
- Wei Y, "Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70years", J Clin Hypertens(Greenwich), 15, pp.420~427 (2013)
- Zhang Y, "Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? : subgroup analyses of findings from the randomized FEVER trial", Eur Heart J, 32, pp.1500~1508 (2011)
- Warwick J, "No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people : an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial(HYVET)study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over", BMC Med, 13, pp.78~ (2015)
- Dahlof B, "Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension(STOP-Hypertension)", Lancet, 338, pp.1281~1285 (1991)
- SHEP Cooperative Research Group, "Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension : final results of the Systolic Hypertension in the Elderly Program(SHEP)", JAMA, 265, pp.3255~3264 (1991)
- Staessen JA, "Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe(Syst-Eur)Trial Investigators", Lancet, 350, pp.757~764 (1997)
- Ambrosius WT, "The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure : the Systolic Blood Pressure Intervention Trial(SPRINT)", Clin Trials, 11, pp.532~546 (2014)
- Zhang S, "Strategy of blood pressure intervention in the elderly hypertensive patients(STEP) : rational, design, and baseline characteristics for the main trial", Contemp Clin Trials, 89, pp.105913~ (2020)